The all Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the all Hub cannot guarantee the accuracy of translated content. The all and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The ALL Hub is an independent medical education platform, sponsored by Jazz Pharmaceuticals, Amgen, and Pfizer and supported through an educational grant from the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View all content recommended for you
Nelarabine injection receives U.S. FDA approval for the treatment of T-ALL and T-LBL
On March 7, 2023, it was announced that nelarabine injection, a prodrug of guanine arabinoside, was approved by the U.S. Food and Drug Administration (FDA) for the treatment of T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma.1,2
This approval is encouraging for pediatric and young adult patients with T-ALL who have not responded to, or have relapsed following, treatment with prior chemotherapeutic agents, addressing a clinical need in this patient group.3
T-ALL is a rare and aggressive subtype of ALL which is most common in children.1 Currently, nelarabine is the only approved treatment for T-ALL in both pediatric and adult patients. The phase III COG AALL0434 trial (NCT00408005) investigating nelarabine and escalating-dose methotrexate in young patients with newly diagnosed T-cell ALL or T-cell lymphoblastic lymphoma, previously reported on the ALL hub, demonstrated promising 5-year survival outcomes; event-free survival, overall survival, and disease-free survival was 88%, 90%, and 91%, respectively.4
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
